Virpax Pharmaceuticals, Inc. has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-3, initially filed on April 18, 2024. The company seeks to have the registration become effective on May 2, 2024, at 5:00 p.m. Eastern Time or as soon thereafter as possible. This request was communicated through a letter addressed to Daniel Crawford at the SEC's Division of Corporation Finance. Virpax Pharmaceuticals acknowledges its responsibilities under federal securities laws regarding the issuance of securities covered by the Registration Statement. The company has also designated Leslie Marlow and Melissa Palat Murawsky from Blank Rome LLP to modify or withdraw the acceleration request if necessary.

Virpax Pharmaceuticals, Inc. has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-3, initially filed on April 18, 2024. The company seeks to have the registration become effective on May 2, 2024, at 5:00 p.m. Eastern Time or as soon thereafter as possible. This request was communicated through a letter addressed to Daniel Crawford at the SEC's Division of Corporation Finance. Virpax Pharmaceuticals acknowledges its responsibilities under federal securities laws regarding the issuance of securities covered by the Registration Statement. The company has also designated Leslie Marlow and Melissa Palat Murawsky from Blank Rome LLP to modify or withdraw the acceleration request if necessary.